文献速递类风湿关节炎

利用数字技术与PROMIS量表评估类风湿关节炎疾病活动度

Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-01-01

基于ArthritisPower注册研究中6154例患者(11275次观察)的数据,采用四种PROMIS计算机自适应测试量表联合疼痛强度和患者总体评估预测RAPID3,模型解释RAPID3总分方差高达97%,最佳模型与观察RAPID3一致性极佳(κ=0.93),Bland-Altman分析无系统偏差。若有PROMIS评分,RAPID3中的多维健康评估问卷和患者总体评估组分可能并非必需。

要点

  • PROMIS CAT量表联合疼痛与总体评估可高度预测RAPID3(R²=0.97),一致性极佳(κ=0.93)。
  • PROMIS量表评估耗时中位数29–116秒,适合数字化高效采集患者报告结局。
  • 若已获取PROMIS评分,RAPID3中MDHAQ和患者总体评估组分可能可省略。

核心结论

  • 观察RAPID3与基于多种PROMIS量表预测的RAPID3评分之间一致性极佳,Bland-Altman分析显示残差差异极小且无系统偏差。

研究设计与样本

  • 在ArthritisPower注册研究中,对6154例符合条件的患者共11275次观察,施用四种PROMIS计算机自适应测试量表(疼痛干扰、躯体功能、睡眠障碍、疲劳)及RAPID3、疼痛强度和患者总体评估。

主要发现

  • 患者平均年龄52.7±10.5岁,93%为女性;评估时间中位数从29秒(PROMIS睡眠障碍)到116秒(RAPID3)。
  • PROMIS CATs彼此之间及与RAPID3呈中等相关(r约0.4–0.7)。
  • PROMIS量表联合疼痛强度和患者总体评估可解释RAPID3评分总方差的97%(R²=0.97)。
  • 最佳一致性的模型中观察RAPID3与CAT-PROMIS预测RAPID3的κ=0.93,Bland-Altman 95%一致性界限显示残差差异极小且无系统偏差。

关键数值与推荐

  • 预测RAPID3的模型R²=0.97;观察与预测RAPID3一致性κ=0.93。
  • PROMIS CATs间及与RAPID3的相关性r约0.4–0.7。

临床怎么用

  • 在数字化采集场景下,可用PROMIS量表联合疼痛强度和患者总体评估替代RAPID3评估类风湿关节炎疾病活动度。
  • 若已获取PROMIS评分,RAPID3中的多维健康评估问卷和患者总体评估组分可能无需重复采集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Health information technology has enabled efficient measurement of patient-reported outcomes (PROs). The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) is becoming more widely adopted for research and routine care, and some PROMIS instruments might be substituted for lengthier, legacy PRO instruments. METHODS: Four PROMIS computer-adaptive testing (CAT) instruments (pain interference, physical function, sleep disturbance, and fatigue) and the Routine Assessment of Patient Index Data 3 (RAPID3), along with pain intensity and patient global assessment score, were administered to participants in the ArthritisPower registry. The RAPID3 was predicted using different combinations of these variables to create a new score (CAT-PROMIS RAPID3). Kappa statistics and Bland-Altman 95% limits of agreement were used to measure agreement between the observed versus predicted RAPID3. RESULTS: A total of 6,154 eligible patients contributed 11,275 observations. The mean ± SD age was 52.7 ± 10.5 years, and 93% of patients were women. The median assessment times ranged from 29 seconds (PROMIS sleep disturbance) to 116 seconds (RAPID3). As single pairwise comparisons, the PROMIS CATs examined were modestly correlated (r approximately 0.4-0.7) to one other and RAPID3. Together with the pain intensity and patient global assessment, the PROMIS instruments explained a high fraction of total variance (R2 = 0.97) of the RAPID3 score. In the model with the highest agreement (κ = 0.93) between the observed RAPID3 and the CAT-PROMIS predicted RAPID3, Bland-Altman 95% limits of agreement showed minimal residual differences and no systematic biases. CONCLUSION: There was excellent agreement between the observed RAPID3 and predicted RAPID3 scores estimated using several PROMIS instruments. The Multidimensional Health Assessment Questionnaire and patient global assessment components of RAPID3 may be unnecessary if PROMIS scores are available.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Yun H, Nowell WB, Curtis D, et al. Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology. Arthritis Care Res (Hoboken). 2020. PMID: 30927515. doi:10.1002/acr.23888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。